"We believe the greatest risk investors in Ligand face is the company may be excluded from government healthcare programs, found in violation of government regulations and face civil and criminal penalties that could result in imprisonment," Lemelson said. "It is inexplicable why the SEC has failed to act, given all of the disturbing developments that have been charted. Protecting the American investor and taxpayer, not to mention the sick who need reliable, affordable access to lifesaving medications must be a priority over fostering cozy relationships with Wall Street," Lemelson continued.
The full letter, is available online here: https://www.scribd.com/document/383785855/Rev-Fr-Emmanuel-Lemelson-Calls-on-Congress-Office-of-Inspector-General-to-Investigate-SEC-Failures
A copy of Fr. Emmanuel's December 2016 letter to the U.S. Senate Special Committee on Aging, is available online here:
https://amvona.com/featured/finding-alpha/item/43503-lantern-foundation-founder-urges-senate-committee-to-commence-investigation-into-ligand-pharmaceuticals
About Rev. Fr. Emmanuel Lemelson:
Rev. Fr. Emmanuel Lemelson is the Chief Investment Officer of Lemelson Capital Management, LLC a Massachusetts-based Global Investment Management firm.
For more information, see: https://www.lemelsoncapital.com/
Lemelson Capital Management, LLC is a member of the Financial Industry Regulatory Authority, CRD number 164969.
For further information, please contact:
Lemelson Capital Management, LLC Investor and Media Relations Telephone: 508-630-2281
View original content:http://www.prnewswire.com/news-releases/rev-fr-emmanuel-lemelson-calls-on-congress-office-of-inspector-general-to-investigate-sec-failures-300680700.html
SOURCE Lemelson Capital Management, LLC